BMS finds replacement for retiring CSO
Bristol-Myers Squibb has announced the appointment of Dr. Thomas J. Lynch, Jr., to the position of Executive Vice President and Chief Scientific Officer. He will take up the position on 16 March when his predecessor, Dr. Francis Cuss, will retire from his position to continue on as an advisor to company for the interim three month period.
Dr. Lynch arrives at BMS with 23 years of experience working at Massachusetts General Hospital (MGH), where he served as Chairman and CEO of Massachusetts General Physicians Organization and as a member of the MGH board. He also had experience serving as a director at Yale Cancer Center.
“We are pleased to welcome Tom to the leadership team at Bristol-Myers Squibb,” said Giovanni Caforio, Chief Executive Officer and Chairman Designate of Bristol-Myers Squibb. “Tom is an internationally recognized oncologist known for his leadership in the treatment of lung cancer and has made significant contributions to the field of targeted therapies throughout his career. Tom brings deep industry knowledge and a sophisticated understanding of the Bristol-Myers Squibb Research & Development program from his experience as a member of our Board. As we transition to our next phase of growth, we are confident Tom is the right person to lead our dynamic R&D organization as we focus on accelerating the development of our Immuno-Oncology medicines and fully realizing the extraordinary potential of our diverse, innovative pipeline. With deep experience as a clinical researcher, leader of large research centers and a practicing physician, Tom brings unique, important and timely perspectives to the business.”
For his part, Dr. Lynch commented: “Throughout my career, I have been devoted to advancing oncology research, with a particular focus on lung cancer. I have seen first-hand Bristol-Myers Squibb’s commitment to making a meaningful difference in the lives of patients, and I am honoured to lead the company’s R&D program, where lung cancer research is a core area of focus in a highly successful Immuno-Oncology development program. I have a strong appreciation for the depth of Bristol-Myers Squibb’s portfolio and rich pipeline in oncology as well as in the fields of cardiovascular diseases, immunoscience and fibrosis. We have a number of significant opportunities and are uniquely positioned to transform cancer care. I am confident that our team will continue to discover and develop innovative medicines that address serious diseases in areas of significant unmet medical need.”
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …
Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …